Evidence map›Paper›PMID 30556619›Full record

ArticleHuman mutation2019

Reanalysis and optimisation of bioinformatic pipelines is critical for mutation detection.

Mark J Cowley, Yu-Chi Liu, Karen L Oliver, Gemma Carvill, Candace T Myers, Velimir Gayevskiy, Martin Delatycki, Danique R M Vlaskamp, Ying Zhu, Heather Mefford and 5 more

Abstract read
In one paragraph

Article in Human mutation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mark J CowleyKinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.ORCID 0000-0002-9519-5714
Yu-Chi LiuPopulation Health and Immunity Division, Walter and Eliza Hall Institute, Melbourne, Australia.
Karen L OliverPopulation Health and Immunity Division, Walter and Eliza Hall Institute, Melbourne, Australia.ORCID 0000-0001-5188-6153
Gemma CarvillKen and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL.ORCID 0000-0003-4945-3628
Candace T MyersDepartment of Pediatrics, University of Washington, Seattle, WA.
Velimir GayevskiyKinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Martin DelatyckiAustin Health, Melbourne, Australia.
Danique R M VlaskampEpilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Australia.
Ying ZhuDepartment of Medical Genetics, Royal North Shore Hospital, St Leonards, Australia.
Heather MeffordDepartment of Pediatrics, University of Washington, Seattle, WA.
Michael F BuckleyNSW Health Pathology Randwick, Sydney, Australia.ORCID 0000-0002-8298-8758
Melanie BahloPopulation Health and Immunity Division, Walter and Eliza Hall Institute, Melbourne, Australia.ORCID 0000-0001-5132-0774
Ingrid E SchefferEpilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Australia.ORCID 0000-0002-2311-2174
Marcel E DingerKinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.ORCID 0000-0003-4423-934X
Tony RoscioliCentre for Clinical Genetics, Sydney Children's Hospital, Randwick, Australia.

Funding

A Genomic Approach to EpilepsyR01NS069605 · NINDS · UNIVERSITY OF WASHINGTON · PI MEFFORD, HEATHER C. · 2010 to 2019
$4.9M
Cancer Institute NSW 13/ECF/1-46Kinghorn FoundationNHMRC 1054618NHMRC 1091593NHMRC 1102971NHMRC 1104831NHMRC AU/1/BA51117NINDS NIH HHS R01 NS069605NSW Health
6 · The paper itself

Abstract

Rapid advances in genomic technologies have facilitated the identification pathogenic variants causing human disease. We report siblings with developmental and epileptic encephalopathy due to a novel, shared heterozygous pathogenic 13 bp duplication in SYNGAP1 (c.435_447dup, p.(L150Vfs*6)) that was identified by whole genome sequencing (WGS). The pathogenic variant had escaped earlier detection via two methodologies: whole exome sequencing and high-depth targeted sequencing. Both technologies had produced reads carrying the variant, however, they were either not aligned due to the size of the insertion or aligned to multiple major histocompatibility complex (MHC) regions in the hg19 reference genome, making the critical reads unavailable for variant calling. The WGS pipeline followed different protocols, including alignment of reads to the GRCh37 reference genome, which lacks the additional MHC contigs. Our findings highlight the benefit of using orthogonal clinical bioinformatic pipelines and all relevant inheritance patterns to re-analyze genomic data in undiagnosed patients.

Indexed as

MutationComputational BiologyDNA Mutational AnalysisGenetic Association StudiesGenome, HumanGenomicsHigh-Throughput Nucleotide SequencingHumansPhenotypeclinical bioinformatics, de novodevelopmental and epileptic encephalopathy, whole genome sequencing

Identifiers

PMID30556619
PMCPMC6492103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.